$71.50
0.00% yesterday
Nasdaq, Oct 23, 10:15 pm CET
ISIN
US4622221004
Symbol
IONS

Ionis Pharmaceuticals, Inc. Stock price

$71.50
+8.93 14.27% 1M
+42.40 145.70% 6M
+36.54 104.52% YTD
+33.08 86.10% 1Y
+26.75 59.78% 3Y
+24.16 51.04% 5Y
+25.98 57.07% 10Y
+66.92 1,461.14% 20Y
Nasdaq, Closing price Thu, Oct 23 2025
+0.00 0.00%
ISIN
US4622221004
Symbol
IONS
Industry

Key metrics

Basic
Market capitalization
$11.4b
Enterprise Value
$10.4b
Net debt
positive
Cash
$2.3b
Shares outstanding
159.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
12.1 | 13.0
EV/Sales
11.0 | 11.8
EV/FCF
negative
P/B
18.0
Financial Health
Equity Ratio
19.6%
Return on Equity
-77.2%
ROCE
-12.8%
ROIC
-45.4%
Debt/Equity
2.0
Financials (TTM | estimate)
Revenue
$944.1m | $874.5m
EBITDA
$-260.1m | $-372.9m
EBIT
$-266.5m | $-413.1m
Net Income
$-268.2m | $-413.8m
Free Cash Flow
$-290.0m
Growth (TTM | estimate)
Revenue
16.1% | 24.0%
EBITDA
25.6% | 19.5%
EBIT
27.4% | 13.0%
Net Income
26.7% | 8.8%
Free Cash Flow
19.0%
Margin (TTM | estimate)
Gross
98.9%
EBITDA
-27.6% | -42.6%
EBIT
-28.2%
Net
-28.4% | -47.3%
Free Cash Flow
-30.7%
More
EPS
$-1.5
FCF per Share
$-1.8
Short interest
10.2%
Employees
1k
Rev per Employee
$660.0k
Show more

Is Ionis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,021 stocks worldwide.

Ionis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

23x Buy
74%
8x Hold
26%

Analyst Opinions

31 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

Buy
74%
Hold
26%

Financial data from Ionis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
944 944
16% 16%
100%
- Direct Costs 11 11
9% 9%
1%
934 934
16% 16%
99%
- Selling and Administrative Expenses 317 317
23% 23%
34%
- Research and Development Expense 883 883
3% 3%
94%
-260 -260
26% 26%
-28%
- Depreciation and Amortization 6.39 6.39
64% 64%
1%
EBIT (Operating Income) EBIT -267 -267
27% 27%
-28%
Net Profit -268 -268
27% 27%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about Ionis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ionis Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
about 17 hours ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey of the biopharmaceutical and related industries. In its first year of eligibility for the award, Ionis was ranked second based on industry-leading innovation, strong alignment of company and employ...
Neutral
Business Wire
3 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis' chief executive officer, was awarded the 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (OTS), a nonprofit organization that fosters academia and industry-based research and development of oligonucleotide therapeutics. The OTS Lifetime A...
Neutral
The Motley Fool
4 days ago
On October 17, 2025, Capricorn Fund Managers Ltd disclosed a new stake in Ionis Pharmaceuticals, acquiring approximately 162,800 shares in a trade estimated at $10.65 million based on average quarterly pricing.
More Ionis Pharmaceuticals, Inc. News

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Head office United States
CEO Brett Monia
Employees 1,069
Founded 1989
Website www.ionis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today